Karyopharm to Participate at 2020 RBC Capital Markets Global Healthcare Virtual Conference

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) announced that CEO Michael Kauffman will participate in a fireside chat at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on May 19, 2020, at 8:35 a.m. ET. A live webcast will be available on their website, with a replay accessible for 90 days post-event. Karyopharm focuses on developing novel drugs targeting nuclear export for cancer treatment. Their lead drug, XPOVIO (selinexor), received FDA accelerated approval in July 2019 for multiple myeloma and is under review in Europe and for additional indications.

NEWTON, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in a fireside chat at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on Tuesday, May 19, 2020 at 8:35 a.m. ET.

A live webcast of the fireside chat can be accessed on the "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the fireside chat.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO^® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. A supplemental New Drug Application was accepted by the FDA seeking accelerated approval for selinexor as a new treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com.

Contacts:

Investors:
Karyopharm Therapeutics Inc.
Ian Karp, Vice President, Investor and Public Relations
857-297-2241 | ikarp@karyopharm.com

Media:
FTI Consulting
Simona Kormanikova or Robert Stanislaro
212-850-5600 |Simona.Kormanikova@fticonsulting.com or robert.stanislaro@fticonsulting.com

FAQ

When will Karyopharm's CEO participate in the RBC Capital Markets Global Healthcare Virtual Conference?

CEO Michael Kauffman will participate on May 19, 2020, at 8:35 a.m. ET.

How can I access the webcast of Karyopharm's fireside chat?

The webcast will be available in the 'Events & Presentations' section of Karyopharm's investor website.

What is Karyopharm Therapeutics known for?

Karyopharm is known for developing first-in-class drugs targeting nuclear export for cancer and other diseases.

What is the status of Karyopharm's lead drug, XPOVIO?

XPOVIO (selinexor) received FDA accelerated approval for multiple myeloma and is under review for additional indications.

How long will the replay of Karyopharm's fireside chat be available?

The replay will be archived for 90 days after the event.